Biosimilars Market Size, Trends, Analysis, and Outlook By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Rheumatoid Arthritis, Chronic & Autoimmune

Biosimilars Market Size, Trends, Analysis, and Outlook By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Rheumatoid Arthritis, Chronic & Autoimmune Disorders, Others), by Country, Segment, and Companies, 2024-2032

The global Biosimilars market size is poised to register 12.5% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Biosimilars market across By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Rheumatoid Arthritis, Chronic & Autoimmune Disorders, Others)

The biosimilars market is characterized by the increasing competition in the biopharmaceutical industry, regulatory pathways for biosimilar approval, and the need for affordable and accessible biologic therapies. By 2030, the market is poised to witness significant growth, driven by the launch of biosimilar products, expanding therapeutic indications, and patent expirations of reference biologics. Further, increasing acceptance by healthcare providers, payers, and patients is expected to drive market expansion, enabling biosimilar manufacturers to capture market share, reduce healthcare costs, and improve patient access to biologic treatments.

Biosimilars Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biosimilars market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biosimilars survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biosimilars industry.

Key market trends defining the global Biosimilars demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Biosimilars Market Segmentation- Industry Share, Market Size, and Outlook to 2032

The Biosimilars industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biosimilars companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Biosimilars industry

Leading Biosimilars companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biosimilars companies.

Biosimilars Market Study- Strategic Analysis Review

The Biosimilars market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

• Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
• Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
• Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
• Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Biosimilars Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Biosimilars industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.

Biosimilars Country Analysis and Revenue Outlook to 2032

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.

North America Biosimilars Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Biosimilars market segments. Similarly, Strong market demand is encouraging Canadian Biosimilars companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Biosimilars market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Biosimilars Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Biosimilars industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Biosimilars market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Biosimilars Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Biosimilars in Asia Pacific. In particular, China, India, and South East Asian Biosimilars markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.

Latin America Biosimilars Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Biosimilars Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biosimilars market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biosimilars.

Biosimilars Market Company Profiles

The global Biosimilars market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Amega Biotech S.A.S., Amgen Inc, Amneal Pharmaceuticals Inc, Apotex Inc, BIOCAD, Biocon Ltd, Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd, Coherus BioSciences Inc, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, Fujifilm Kyowa Kirin Biologics Co. Ltd, Intas Pharmaceuticals Ltd, Kashiv Biosciences LLC, mAbxience S.L., Novartis AG, Pfizer Inc, Probiomed S.A. de C.V., Reliance Life Sciences Pvt. Ltd, Samsung Bioepis Co. Ltd, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd, USV Private Ltd.

Recent Biosimilars Market Developments

The global Biosimilars market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Biosimilars Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

• Pricing Analysis
• Value Chain Analysis
• SWOT Profile
• Market Dynamics- Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• Macroeconomic Impact Analysis
• Case Scenarios- Low, Base, High

Market Segmentation:

By Product

Recombinant Non-glycosylated Proteins

Recombinant Glycosylated Proteins

By Application

Oncology

Blood Disorders

Growth Hormonal Deficiency

Rheumatoid Arthritis

Chronic & Autoimmune Disorders

Others

Geographical Segmentation:

• North America (3 markets)
• Europe (6 markets)
• Asia Pacific (6 markets)
• Latin America (3 markets)
• Middle East Africa (5 markets)

Companies

Amega Biotech S.A.S.

Amgen Inc

Amneal Pharmaceuticals Inc

Apotex Inc

BIOCAD

Biocon Ltd

Boehringer Ingelheim International GmbH

Celltrion Healthcare Co. Ltd

Coherus BioSciences Inc

Dr. Reddy's Laboratories Ltd

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Fresenius SE & Co. KGaA

Fujifilm Kyowa Kirin Biologics Co. Ltd

Intas Pharmaceuticals Ltd

Kashiv Biosciences LLC

mAbxience S.L.

Novartis AG

Pfizer Inc

Probiomed S.A. de C.V.

Reliance Life Sciences Pvt. Ltd

Samsung Bioepis Co. Ltd

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd

USV Private Ltd

Formats Available: Excel, PDF, and PPT